You are here

A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

Last updated on April 2, 2019

FOR MORE INFORMATION
Study Location
Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California, 90095 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms, Breast Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or
for which no standard therapy is available

- Previously treated metastatic triple negative breast cancer that expresses Notch3
with at least one measurable lesion

- Adequate bone marrow, renal and liver function

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of
starting study treatment

- Patients with known symptomatic brain metastases requiring steroids

- Prior treatment with a compound of the same mechanism

NCT02129205
Pfizer
Terminated
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neoplasms, Breast Neoplasms
NCT03343054
All Genders
20+
Years
Multiple Sites
Ovarian Cancer HR+ HER2- Metastatic Breast Cancer
NCT03519178
All Genders
18+
Years
Multiple Sites
Hormone Receptor Positive Advanced Breast Cancer, Metastatic Breast Cancer, Human Epidermal Receptor 2 Negative Advanced Breast Cancer, Castration Resistant Prostate Cancer
NCT03685591
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now